FDA Accepts New Drug Application for Nubeqa Combo for Prostate Cancer Subset
The Food and Drug Administration (FDA) accepted a supplemental new drug application for Nubeqa (darolutamide) plus androgen deprivation therapy to treat metastatic hormone-sensitive prostate cancer. The application’s acceptance was announced in a press …